According to the agreement, Oncobiologics will have access to XOMA’s diverse library of single-chain variable fragments antibodies and associated patent estate, and will utilize XOMA’s know-how and proven software tools. Financial terms were kept confidential.
Oncobiologics founder and CEO Pankaj Mohan said that XOMA’s technology represents an important asset to support the company’s strategy to deliver improved efficacy and safety in our drug candidates.
"Access to this technology is a key differentiator for the bi-specific mAb candidates in our pipeline and we believe this creates significant value for our programs," Mohan added.
The Oncobiologics will utilize the technology platform to develop novel biotherapeutics based on engineering single-chain variable fragments into a bi-specific antibody scaffold.
Oncobiologics has selected clinically validated targets that will be used in the development of its bi-specific antibody platform targeting three therapeutic areas oncology, immuno-oncology and immunology.